Bergen, Norway, 30 November 2020 - BerGenBio ASA (OSE:BGBIO), a
clinical-stage<br />
biopharmaceutical company developing novel, selective AXL kinase inhibitors
for<br />
severe unmet medical need, is pleased to announce it has been accepted for a<br
/>
poster presentation at the 62[nd]  Annual American Society of Hematology
(ASH)<br />
Meeting, being held virtually from 5-8 December 2020.<br />
<br />
The poster will provide an update from the Company's Phase II study of<br />
bemcentinib (BGBC003) in combination with low dose cytarabine (LDAC) in
elderly<br />
relapsed AML patients, and the Phase II BERGAMO trial in patients with
high-risk<br />
MDS or AML.<br />
<br />
Abstracts have been announced online, and details of the presentation are
below.<br />
<br />
Title: The Combination of AXL Inhibitor Bemcentinib and Low Dose Cytarabine
Is<br />
Well Tolerated and Efficacious in Elderly Relapsed AML Patients: Update from
the<br />
Ongoing BGBC003 phase II Trial (NCT02488408)<br />
<br />
Date: Sunday, December 6, 2020<br />
<br />
Session name: 613. Acute Myeloid Leukemia: Clinical Studies: Poster II<br />
<br />
Time: 7.00am - 3.30pm (Pacific Time) / 4.00pm - 12.30am (7[th] Dec) (CET)<br />
<br />
Link online to abstract<br />
here (https://ash.confex.com/ash/2020/webprogram/Paper136566.html)<br />
<br />
Title: Efficacy and Safety of Bemcentinib in Patients with Myelodysplastic<br />
Syndromes or Acute Myeloid Leukemia Failing Hypomethylating Agents<br />
<br />
Date: Saturday, December 5, 2020<br />
<br />
Session name: 637 Myelodysplastic Syndromes - Clinical Studies: Poster I<br />
Hematology Disease Topics & Pathways: Diseases, Therapies, MDS, Myeloid<br />
Malignancies, Clinically relevant<br />
<br />
Time: 7.00am - 3.30pm (Pacific Time) / 4.00pm - 12.30am (7[th] Dec) (CET)<br />
<br />
Link online to abstract<br />
here (https://ash.confex.com/ash/2020/webprogram/Paper140240.html)<br />
<br />
The poster will be available at www.bergenbio.com in the section:<br />
Investors/Presentations at the date of the ASH 2020 meeting.<br />
<br />
- End -<br />
<br />
About AML and the BGBC003 trial<br />
<br />
Acute myeloid leukaemia (AML) is a rapidly progressing blood cancer. AML is
the<br />
most common form of acute leukaemia in adults, where malignant AML blasts<br />
interfere with the normal functioning of the bone marrow leading to a
multitude<br />
of complications like anaemia, infections and bleeding. AML is diagnosed in
over<br />
20,000 patients in the US annually and is rapidly lethal if left untreated.<br
/>
Successful treatment typically requires intensive therapy or bone marrow<br />
transplantation, and relapse and resistance are common. Consequently, there
is<br />
an urgent need for effective novel therapies in relapsed/refractory patients,<br
/>
particularly those that are ineligible for intensive therapy or bone marrow<br
/>
transplant.<br />
<br />
The BGBC003 trial is a phase Ib/II multi-centre open label study of
bemcentinib<br />
in combination with cytarabine (part B2) and decitabine (part B3) in patients<br
/>
with AML who are unsuitable for intensive chemotherapy as a result of
advanced<br />
age or existing comorbidities. Up to 28 patients will be enrolled at centres
in<br />
the US, Norway, Germany and Italy.<br />
<br />
For more information please access trial NCT02488408 at
www.clinicaltrials.gov.<br />
<br />
About BerGenBio ASA<br />
<br />
BerGenBio is a clinical-stage biopharmaceutical company focused on developing<br
/>
transformative drugs targeting AXL as a potential cornerstone of therapy for<br
/>
aggressive diseases, including immune-evasive, therapy resistant cancers. The<br
/>
company's proprietary lead candidate, bemcentinib, is a potentially first-in<br
/>
-class selective AXL inhibitor in a broad phase II clinical development<br />
programme focused on combination and single agent therapy in lung cancer,<br />
leukaemia and COVID-19. A first-in-class functional blocking anti-AXL
antibody,<br />
tilvestamab, is undergoing phase I clinical testing. In parallel, BerGenBio
is<br />
developing a companion diagnostic test to identify patient populations most<br
/>
likely to benefit from bemcentinib: this is expected to facilitate more<br />
efficient registration trials supporting a precision medicine-based<br />
commercialisation strategy.<br />
<br />
BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The<br />
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more<br />
information, visit www.bergenbio.com<br />
<br />
Contacts<br />
<br />
Richard Godfrey CEO, BerGenBio ASA<br />
+47 917 86 304<br />
<br />
Rune Skeie, CFO, BerGenBio ASA<br />
rune.skeie@bergenbio.com<br />
+47 917 86 513<br />
<br />
International Media Relations<br />
<br />
Mary-Jane Elliott, Chris Welsh, Lucy Featherstone, Carina Jurs<br />
<br />
Consilium Strategic Communications<br />
bergenbio@consilium-comms.com<br />
+44 20 3709 5700<br />
<br />
Media Relations in Norway<br />
<br />
Jan Petter Stiff, Crux Advisersstiff@crux.no<br />
+47 995 13 891<br />
<br />
Forward looking statements<br />
<br />
This announcement may contain forward-looking statements, which as such are
not<br />
historical facts, but are based upon various assumptions, many of which are<br
/>
based, in turn, upon further assumptions. These assumptions are inherently<br />
subject to significant known and unknown risks, uncertainties and other<br />
important factors. Such risks, uncertainties, contingencies and other
important<br />
factors could cause actual events to differ materially from the expectations<br
/>
expressed or implied in this announcement by such forward-looking statements.<br
/>
<br />
This information is subject to the disclosure requirements pursuant to section
5<br />
-12 of the Norwegian Securities Trading Act.